降压治疗适应症患者跌倒风险预测模型的开发与外部验证:回顾性队列研究
本研究利用英国临床实践研究数据链(CPRD)中的电子健康记录,针对40岁及以上、血压在130-179 mmHg之间有降压治疗适应症的患者,开发并外部验证了STRATIFY-Falls临床预测模型,用于识别10年内因跌倒住院或死亡的风险。模型包含24个预测因子,外部验证显示5年和10年的汇总C统计量分别为0.833和0.843,区分度良好,但校准度欠佳,10年观察与期望比为1.839,决策曲线分析提示在10%风险阈值附近具有潜在临床效用。
要点
- STRATIFY-Falls模型可较好区分有降压治疗适应症患者未来1-10年的跌倒高风险与低风险。
- 外部验证中模型区分度良好(5年C统计量0.833,10年0.843),但存在低估风险。
- 决策曲线分析提示模型在10%风险阈值附近有潜在临床效用,可辅助识别需加强监测或早期干预的高危患者。
核心结论
- 该预测模型利用常规记录的临床特征,能较好区分有降压治疗适应症患者未来1-10年跌倒高风险与低风险。
- 尽管外部验证显示校准不佳,但模型在10%风险阈值附近仍具有潜在临床效用,可帮助识别高危患者以进行更密切监测或早期干预。
研究设计与样本
- 回顾性队列研究,使用英国临床实践研究数据链(CPRD)初级保健电子健康记录。
- 纳入40岁及以上、至少有一次血压测量值在130 mmHg至179 mmHg之间的患者。
- 模型开发使用CPRD GOLD数据,采用Fine-Gray方法考虑其他原因死亡的竞争风险,并在1年、5年和10年使用伪值重新校准。
- 外部验证使用CPRD Aurum数据,通过校准曲线、观察与期望比、C统计量和D统计量评估性能,并用决策曲线分析评估临床效用。
主要发现
- 模型开发队列包含1 772 600名患者,发生62 691例严重跌倒;外部验证队列包含3 805 366名患者,发生206 956例严重跌倒。
- 最终模型包含24个预测因子,包括年龄、性别、 ethnicity、酒精消费、居住在高社会剥夺地区、跌倒史、多发性硬化症以及降压药、抗抑郁药、催眠药和抗焦虑药的处方。
- 外部验证中,重新校准后的模型5年和10年汇总C统计量分别为0.833(95%CI 0.831-0.835)和0.843(95%CI 0.841-0.844)。
- 原始模型校准目测不佳,重新校准后仍有低估风险,10年观察与期望比为1.839(95%CI 1.811-1.865)。
- 决策曲线分析显示净获益大于其他策略,提示潜在临床效用。
关键数值与推荐
- 严重跌倒定义为索引日期(队列 entry 后12个月)后10年内以跌倒为主要诊断的住院或死亡。
- 模型预测1-10年内严重跌倒风险,外部验证5年C统计量0.833(95%CI 0.831-0.835),10年0.843(95%CI 0.841-0.844)。
- 10年观察与期望比1.839(95%CI 1.811-1.865),提示风险低估。
- 决策曲线分析在10%阈值附近显示净获益,提示潜在临床效用。
临床怎么用
- 该模型可用于有降压治疗适应症的患者,帮助识别未来1-10年跌倒高风险个体,以考虑更密切监测或早期干预。
- 临床使用时应注意模型可能低估风险,尤其在外部验证中10年观察与期望比为1.839。
- 模型在10%风险阈值附近具有潜在临床效用,但最佳阈值需进一步研究以最大化临床效用和成本效益。
局限性
- 外部验证中模型校准不佳,重新校准后仍存在风险低估(10年观察与期望比1.839)。
- 研究为回顾性队列,使用电子健康记录数据,可能存在记录不完整或误分类。
- 需要进一步研究探索合适的阈值以最大化模型的临床效用和成本效益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To develop and externally validate the STRAtifying Treatments In the multi-morbid Frail elderlY (STRATIFY)-Falls clinical prediction model to identify the risk of hospital admission or death from a fall in patients with an indication for antihypertensive treatment. DESIGN: Retrospective cohort study. SETTING: Primary care data from electronic health records contained within the UK Clinical Practice Research Datalink (CPRD). PARTICIPANTS: Patients aged 40 years or older with at least one blood pressure measurement between 130 mm Hg and 179 mm Hg. MAIN OUTCOME MEASURE: First serious fall, defined as hospital admission or death with a primary diagnosis of a fall within 10 years of the index date (12 months after cohort entry). Model development was conducted using a Fine-Gray approach in data from CPRD GOLD, accounting for the competing risk of death from other causes, with subsequent recalibration at one, five, and 10 years using pseudo values. External validation was conducted using data from CPRD Aurum, with performance assessed through calibration curves and the observed to expected ratio, C statistic, and D statistic, pooled across general practices, and clinical utility using decision curve analysis at thresholds around 10%. RESULTS: Analysis included 1 772 600 patients (experiencing 62 691 serious falls) from CPRD GOLD used in model development, and 3 805 366 (experiencing 206 956 serious falls) from CPRD Aurum in the external validation. The final model consisted of 24 predictors, including age, sex, ethnicity, alcohol consumption, living in an area of high social deprivation, a history of falls, multiple sclerosis, and prescriptions of antihypertensives, antidepressants, hypnotics, and anxiolytics. Upon external validation, the recalibrated model showed good discrimination, with pooled C statistics of 0.833 (95% confidence interval 0.831 to 0.835) and 0.843 (0.841 to 0.844) at five and 10 years, respectively. Original model calibration was poor on visual inspection and although this was improved with recalibration, under-prediction of risk remained (observed to expected ratio at 10 years 1.839, 95% confidence interval 1.811 to 1.865). Nevertheless, decision curve analysis suggests potential clinical utility, with net benefit larger than other strategies. CONCLUSIONS: This prediction model uses commonly recorded clinical characteristics and distinguishes well between patients at high and low risk of falls in the next 1-10 years. Although miscalibration was evident on external validation, the model still had potential clinical utility around risk thresholds of 10% and so could be useful in routine clinical practice to help identify those at high risk of falls who might benefit from closer monitoring or early intervention to prevent future falls. Further studies are needed to explore the appropriate thresholds that maximise the model's clinical utility and cost effectiveness.
引用
- Archer L, Koshiaris C, Lay-Flurrie S, et al. Development and external validation of a risk prediction model for falls in patients with an indication for antihypertensive treatment: retrospective cohort study. BMJ. 2022. PMID: 36347531. doi:10.1136/bmj-2022-070918
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。